G
Glen A Kennedy
Researcher at Royal Brisbane and Women's Hospital
Publications - 142
Citations - 2431
Glen A Kennedy is an academic researcher from Royal Brisbane and Women's Hospital. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 25, co-authored 126 publications receiving 2041 citations. Previous affiliations of Glen A Kennedy include University of Queensland & Peter MacCallum Cancer Centre.
Papers
More filters
Journal ArticleDOI
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
Nimitha R. Mathew,Nimitha R. Mathew,Francis Baumgartner,Lukas Braun,David O’Sullivan,Simone Thomas,Miguel Waterhouse,Tony Andreas Müller,Kathrin Hanke,Kathrin Hanke,Sanaz Taromi,Petya Apostolova,Anna Lena Illert,Wolfgang Melchinger,Sandra Duquesne,Annette Schmitt-Graeff,Lena Osswald,Kai-Li Yan,Arnim Weber,Sonia Tugues,Sabine Spath,Dietmar Pfeifer,Marie Follo,Rainer Claus,Michael Lübbert,Christoph Rummelt,Hartmut Bertz,Ralph Wäsch,Johanna Haag,Andrea Schmidts,Michael Schultheiss,Dominik Bettinger,Robert Thimme,Evelyn Ullrich,Yakup Tanriver,Giang Lam Vuong,Renate Arnold,Philipp Hemmati,Dominik Wolf,Markus Ditschkowski,Cordula A. Jilg,Konrad Wilhelm,C. Leiber,Sabine Gerull,Jörg Halter,Claudia Lengerke,Thomas Pabst,Thomas Schroeder,Guido Kobbe,Wolf Rösler,Soroush Doostkam,Stephan Meckel,Kathleen Stabla,Kathleen Stabla,S K Metzelder,S K Metzelder,Sebastian Halbach,Tilman Brummer,Zehan Hu,Zehan Hu,Joern Dengjel,Joern Dengjel,Björn Hackanson,Christoph Schmid,Udo Holtick,Christof Scheid,Alexandros Spyridonidis,Friedrich Stölzel,Rainer Ordemann,Lutz P. Müller,Flore Sicre-de-Fontbrune,Gabriele Ihorst,Jürgen Kuball,Jan E. Ehlert,Daniel Feger,Eva-Maria Wagner,Jean-Yves Cahn,Jacqueline Schnell,Florian Kuchenbauer,Donald Bunjes,Ronjon Chakraverty,Simon Richardson,Saar Gill,Nicolaus Kröger,Francis Ayuk,Luca Vago,Fabio Ciceri,Antonia M.S. Müller,Takeshi Kondo,Takanori Teshima,Susan Klaeger,Susan Klaeger,Bernhard Kuster,Dennis Dong Hwan Kim,Daniel J. Weisdorf,Walter J.F.M. van der Velden,Daniela Dörfel,Wolfgang Bethge,Inken Hilgendorf,Andreas Hochhaus,Geoffroy Andrieux,Melanie Börries,Hauke Busch,John M. Magenau,Pavan Reddy,Myriam Labopin,Joseph H. Antin,Andrea S. Henden,Andrea S. Henden,Geoffrey R. Hill,Geoffrey R. Hill,Glen A Kennedy,Merav Bar,Anita Sarma,Donal P. McLornan,Ghulam J. Mufti,Betul Oran,Katayoun Rezvani,Omid Shah,Robert S. Negrin,Arnon Nagler,Marco Prinz,Marco Prinz,Andreas Burchert,Andreas Neubauer,Andreas Neubauer,Dietrich W. Beelen,Andreas Mackensen,Nikolas von Bubnoff,Wolfgang Herr,Burkhard Becher,Gérard Socié,Michael A. Caligiuri,Eliana Ruggiero,Chiara Bonini,Georg Häcker,Justus Duyster,Jürgen Finke,Erika L. Pearce,Bruce R. Blazar,Robert Zeiser,Robert Zeiser +141 more
TL;DR: Findings indicate that the synergism of T cells and sorafenib is mediated via reduced ATF4 expression, causing activation of the IRF7–IL-15 axis in leukemia cells and thereby leading to metabolic reprogramming of leukemia-reactive T cells in humans.
Journal ArticleDOI
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
Glen A Kennedy,Glen A Kennedy,Antiopi Varelias,Slavica Vuckovic,Laetitia Le Texier,Kate H. Gartlan,Ping Zhang,Gethin P. Thomas,Lisa Anderson,Glen M. Boyle,Nicole Cloonan,Justine Leach,Justine Leach,Elise Sturgeon,Elise Sturgeon,Judy Avery,Judy Avery,Stuart D. Olver,Mary Lor,Ashish Misra,Cheryl Hutchins,A. James Morton,Simon Durrant,Elango Subramoniapillai,Jason Butler,Cameron Curley,Kelli P. A. MacDonald,Siok-Keen Tey,Siok-Keen Tey,Geoffrey R. Hill,Geoffrey R. Hill +30 more
TL;DR: Immune reconstitution was preserved in recipients of interleukin-6 receptor inhibition, but qualitatively modified with suppression of known pathogenic STAT3-dependent pathways and a randomised, controlled trial assessing tocilizumab in addition to standard GVHD prophylaxis in patients is warranted.
Journal ArticleDOI
Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab.
Glen A Kennedy,John F. Seymour,Max Wolf,Henry Januszewicz,Jill Davison,Christopher McCormack,Gail Ryan,Henry Miles Prince +7 more
TL;DR: A phase II study to evaluate the safety, tolerability and efficacy of alemtuzumab in patients with relapsed or refractory advanced stage cutaneous T‐cell lymphoma.
Journal ArticleDOI
Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.
Glen A Kennedy,Siok-Keen Tey,Ralph Cobcroft,Paula Marlton,Gavin Cull,Karen Grimmett,Damien Thomson,Devinder Gill +7 more
TL;DR: In this article, the authors examined the incidence and nature of CD20 negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma (NHL) treated at their institution.
Journal Article
Incidence and nature of CD20 negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: A retrospective review.
TL;DR: It is concluded that loss of CD20 expression in aggressive B‐cell NHL relapsing post‐rituximab therapy is common and repeat tissue biopsy should be undertaken to document CD20expression by both flow cytometry and immunohistochemistry prior to considering repeated courses of rituximAB in relapsed aggressive lymphomas.